Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Medpace is lead sponsor; 0 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13D/A2026-09-28SCHEDULE 13D/A
- SCHEDULE 13G2026-08-14SCHEDULE 13G
- 10-Q2026-07-23Quarterly report
- 8-K2026-07-22Current report (material event)
- 8-K2026-06-04Current report (material event)
- 8-K2026-05-19Current report (material event)
- 10-Q2026-04-23Quarterly report
- 8-K2026-04-22Current report (material event)
- DEFA14A2026-04-01DEFA14A
- DEF 14A2026-04-01Proxy statement
- ARS2026-04-01Annual report to holders
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- PRE 14A2026-03-16PRE 14A
- 10-K2026-02-10Annual report
- 8-K2026-02-09Current report (material event)
- SCHEDULE 13D/A2025-12-01SCHEDULE 13D/A
- 10-Q2025-10-23Quarterly report
- 8-K2025-10-22Current report (material event)
- 10-Q2025-07-22Quarterly report
- 8-K2025-07-21Current report (material event)
- 8-K2025-05-16Current report (material event)
- 10-Q2025-04-22Quarterly report
- 8-K2025-04-21Current report (material event)
- DEFA14A2025-04-02DEFA14A
- DEF 14A2025-04-02Proxy statement
- ARS2025-04-02Annual report to holders
- 8-K2025-03-31Current report (material event)
- SCHEDULE 13D/A2025-03-11SCHEDULE 13D/A
- 10-K2025-02-11Annual report
- 8-K2025-02-10Current report (material event)
- 10-Q2024-10-22Quarterly report
- 8-K2024-10-21Current report (material event)
- 10-Q2024-07-23Quarterly report
- 8-K2024-07-22Current report (material event)
- 8-K2024-07-03Current report (material event)
- 8-K2024-05-21Current report (material event)
- 10-Q2024-04-23Quarterly report
- 8-K2024-04-22Current report (material event)
- DEFA14A2024-04-03DEFA14A
- DEF 14A2024-04-03Proxy statement
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.